A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer
- GynOnco Group Team
- Aug 15
- 1 min read
Updated: Aug 16
STUDY ID: NCT06459180
STATUS: Enrolling
CONDITION: Cervical Cancer SPONSOR: Merck Sharp & Dohme LLC FOR MORE INFORMATION VISIT: https://clinicaltrials.gov/study/NCT06459180
